A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19.

Antimicrob Agents Chemother · 2023 · PMC9872678 · PMID 36515544

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A Kaplan-Meier plot for times to clinical improvement in the FAS and mFAS showed a trend of faster clinical improvement in the camostat group, especially from day 4 to day 10 ( Fig. 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.